Patent Application: Antibodies Binding Human 4Ig-B7H3
Summary
The USPTO has published a new patent application (US20260085122A1) filed by BeOne Medicines I GmbH. The application relates to antibodies or antigen-binding fragments thereof that bind to human 4Ig-B7H3.
What changed
The United States Patent and Trademark Office (USPTO) has published a new patent application, US20260085122A1, filed on September 16, 2025, by BeOne Medicines I GmbH. The application, titled 'Antibodies binding human 4Ig-B7H3, patent application filed 2025', describes antibodies or antigen-binding fragments that bind to human 4Ig-B7H3.
This publication represents a new patent application filing and does not impose immediate compliance obligations on regulated entities. However, it signifies potential future intellectual property developments in the field of antibody therapeutics, which may impact research and development strategies for pharmaceutical and biotechnology companies. Companies operating in this space should monitor patent filings for competitive intelligence and potential licensing opportunities or challenges.
Source document (simplified)
ANTI-B7H3 ANTIBODIES AND METHODS OF USE
Application US20260085122A1 Kind: A1 Mar 26, 2026
Assignee
BeOne Medicines I GmbH
Inventors
Liang QU, Yao DING, Ya ZHANG
Abstract
The present disclosure provides for antibodies or antigen-binding fragments thereof that bind to human 4Ig-B7H3.
CPC Classifications
C07K 16/2827 C07K 2317/24 C07K 2317/31 C07K 2317/41 C07K 2317/565 C07K 2317/569 C07K 2317/92
Filing Date
2025-09-16
Application No.
19329961
Named provisions
Related changes
Source
Classification
Who this affects
Taxonomy
Browse Categories
Get Pharma & Drug Safety alerts
Weekly digest. AI-summarized, no noise.
Free. Unsubscribe anytime.
Get alerts for this source
We'll email you when ChangeBridge: Patent Apps - Peptides (C07K) publishes new changes.